Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism
Frontiers in Pharmacology · 12.06.2026 · 17
DOI: 10.3389/fphar.2026.1854265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.06.2026. Verfasst von Jiao Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Engineering Research…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Phillygenin (PLE) is a bioactive constituent of Forsythiae fructus that exerts hepatoprotective, anti-inflammatory, and antitumor effects. However, its role in hepatocellular carcinoma (HCC) and the mechanisms underlying its activity remain insufficiently characterized.
Methods
The effect of PLE on HCCLM3 and Hep3B tumor cells was assessed using immunofluorescence (IF) staining, TUNEL assay, qRT-PCR, and Western blotting experimental methodology. RNA-sequencing (RNA-seq) was used to detect changes in gene expression and to explore the gene targets and related pathways. Liquid chromatography–mass spectrometry (LC–MS) was used to identify the effects of PLE on primary metabolite targets and metabolism-related pathways. Tumor xenograft models were used for in vivo verification.
Results
PLE inhibited HCC cell proliferation through the inhibition of cell cycle progression and induction of cell apoptosis in vitro, indicating a dual antiproliferative and pro-apoptotic effect. These responses were associated with the modulation of the TNF signaling pathway. Moreover, PLE induced significant alterations in the central carbon metabolism, including the regulation of citrate synthesis and upregulation of oxoglutarate dehydrogenase (OGDH) expression in HCC cells. Finally, PLE treatment significantly reduced tumor growth in vivo , thereby confirming its therapeutic potential.
Conclusion
PLE exerts antitumor effects in HCC through the coordinated regulation of tricarboxylic acid (TCA) cycle metabolism while simultaneously inhibiting the TNF signaling pathway, highlighting its potential as a candidate antitumor drug for the treatment of HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Engineering Research Center of Antitumor Natural Drugs, Natural Drug Intervention in Aging…
- Chongqing University Three Gorges Hospital, Chongqing, China.
Zitieren
APA
Luo, J., Liu, C., Pang, Y., & Pan, L. (2026). Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1854265
Vancouver
Luo J, Liu C, Pang Y, Pan L. Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1854265
BibTeX
@article{Luo2026,
author = {Luo, Jiao and Liu, Chang and Pang, Yi and Pan, Lianhong},
title = {Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1854265}
}
EUVIMED